New imaging clues could help tailor breast cancer care
NCT ID NCT07587086
First seen May 15, 2026 · Last updated Jun 16, 2026 · Updated 8 times
Summary
This study is testing whether a detailed PET/MR scan using a radioactive tracer called fluorocholine can predict the molecular subtype and likely outcomes of breast cancer. Researchers will scan 195 women before they start treatment and compare the images with their actual tumor type and response. The goal is to see if this imaging approach can help doctors choose the best treatment for each patient without needing extra biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan, 11217, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.